Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2015-11-06 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2015). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital structure, even though it is a monthly update rather than a specific transaction announcement. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or director dealing (DIRS).
2015-11-06 French
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document explicitly details 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) executed between 26/10/2015 and 30/10/2015. It provides a table showing the number of shares bought ('ACHAT') and the total amount. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). Therefore, the appropriate filing code is POS.
2015-11-02 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 99% confidence The document explicitly details 'Disclosure of transactions in own shares' over a specific period (26/10/2015 to 30/10/2015), showing the number of shares purchased and the average price. This directly corresponds to the definition of a report concerning the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). The document is not a general announcement of a report (RPA) but the actual transaction data.
2015-11-02 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 100% confidence The document is a press release from Ipsen titled 'Chiffre d'affaires du 3ème trimestre et des neuf premiers mois de 2015'. It provides a summary of quarterly financial performance, including revenue breakdowns by product line, comparisons to previous periods, and management commentary on business trends and outlook. It is an initial announcement of financial results rather than a full interim report or a regulatory filing. Therefore, it fits the definition of an Earnings Release (ER). 9M 2015
2015-10-29 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 28, 2015, announcing a definitive exclusive licensing agreement between Telesta Therapeutics and Ipsen regarding the drug MCNA1 for bladder cancer. It details the financial terms, territories covered, and the status of regulatory filings (FDA Priority Review). This type of announcement, detailing a significant business development such as a licensing deal, partnership, or major financing event, aligns best with the 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a required regulatory disclosure. However, since it explicitly details the terms of a licensing agreement and associated financial considerations (up to $137 million), it is a core business transaction announcement. Given the provided definitions, 'Capital/Financing Update' (CAP) is the most appropriate fit as licensing deals often involve significant capital structure implications or funding milestones, although 'Regulatory Filings' (RNS) is a possibility if this were a generic disclosure. Since the core content is the deal structure and financial arrangement, CAP is selected over the general RNS fallback. It is not an ER, IR, 10-K, or CT.
2015-10-28 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces an "exclusive license agreement" between two companies (Telesta Therapeutics and Ipsen) regarding a drug candidate (MCNA1). It details financial terms (upfront payment, milestones, royalties) and strategic business development. This type of announcement, detailing a significant corporate transaction (licensing/partnership) and associated financial structure, fits best under the Capital/Financing Update category, as it directly relates to the company's financial structure and future revenue streams derived from asset monetization/licensing. While it is a press release, it is more specific than the general 'RNS' fallback. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA), but rather a specific corporate action announcement related to capital/asset value.
2015-10-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.